相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
终止
1
100.0%
暂无批准数据
- The pneumococcal disease pipeline features over 20 drugs from 18+ companies in various clinical and preclinical stages, addressing a significant global health threat. - Sanofi's PCV21, a 21-valent pneumococcal conjugate vaccine in Phase III, leads the late-stage pipeline targeting both pediatric and adult populations worldwide. - Vaxcyte's VAX-31 received FDA Breakthrough Therapy designation and showed strong immune responses in Phase I/II trials involving 1,015 adults aged 50 and older. - The market is driven by high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives, particularly in developing regions.
- Alopexx, Inc. has received investment from Biotech Consortia, Inc. to support the development and commercialization of its antimicrobial vaccine, AV0328. - AV0328 targets poly N-acetyl glucosamine (PNAG), found on various pathogens, and has shown promise in preclinical studies against over 15 different pathogens. - A Phase I trial demonstrated AV0328's tolerability and its ability to induce antibodies capable of killing a wide range of PNAG-expressing pathogens. - The investment will bolster Alopexx's clinical programs and advance its broad-spectrum anti-microbial vaccine, potentially addressing the growing threat of antimicrobial resistance.
